Clinical Trial Update: A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. [Phase 2]

View source ↗

Summary

A completed Phase 2 study evaluating four doses of BI 409306 versus placebo over 12 weeks in schizophrenia patients on stable antipsychotic therapy; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• BI 409306

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2017-10-19